1,090 results

#154948-AAV5

Ready-to-use AAV5 particles produced from CaMKII-somBiPOLES-mCerulean (#154948). In addition to the viral particles, you will also receive purified CaMKII-somBiPOLES-mCerulean plasmid DNA. CamKII-driven expression of soma-targeted BiPOLES for optogenetic inhibition (blue light) and activation (red light). These AAV preparations are suitable purity for injection into animals.

Simon Wiegert

Vierock et al Nat Commun. 2021 Jul 26;12(1):4527. doi:

Sept. 1, 2021

Academic Institutions and Nonprofits only

#125560-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-dLight1.3b (#125560). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.3b plasmid DNA. CAG-driven expression of dLight1.3b dopamine sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

May 6, 2021

Academic Institutions and Nonprofits only

#137135-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-oScarlet (#137135). In addition to the viral particles, you will also receive purified pAAV-Ef1a-oScarlet plasmid DNA. EF1a-driven expression of oScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#98930-AAV9

Ready-to-use AAV9 particles produced from pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 (#98930). In addition to the viral particles, you will also receive purified pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 plasmid DNA. GFAP-driven glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

April 13, 2018

Academic Institutions and Nonprofits only

#105558-AAVrg

Ready-to-use AAV Retrograde particles produced from pENN.AAV.CamKII 0.4.Cre.SV40 (#105558). In addition to the viral particles, you will also receive purified pENN.AAV.CamKII 0.4.Cre.SV40 plasmid DNA. CamKII-driven Cre expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Oct. 21, 2024

Academic Institutions and Nonprofits only

#191706-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP13044 - pAAV-AiE0779m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3044) (#191706). In addition to the viral particles, you will also receive purified AiP13044 - pAAV-AiE0779m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3044) plasmid DNA. SYFP2-expression in striatal direct pathway medium spiny neurons (D1-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

July 15, 2024

Academic Institutions and Nonprofits only

#137133-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-mCherry (#137133). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-mCherry plasmid DNA. EF1a-driven, Cre-dependent expression of mCherry (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#87306-AAV5

Ready-to-use AAV5 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

July 22, 2020

Academic Institutions and Nonprofits only

#112677-AAV1

Ready-to-use AAV1 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Dec. 2, 2019

Academic Institutions and Nonprofits only

#232351-AAV5

Ready-to-use AAV5 particles produced from pAAV-ATLASsnCre (#232351). In addition to the viral particles, you will also receive purified pAAV-ATLASsnCre plasmid DNA. Syn-driven, ATLASsnCre expression. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Rivera et al Nat Methods. 2025 May;22(5):1101-1111. d

Sept. 22, 2025

Academic Institutions and Nonprofits only

#174378-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-syn-Flpo (#174378). In addition to the viral particles, you will also receive purified pAAV-syn-Flpo plasmid DNA. Syn-driven expression of the recombinase FLPo. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Jin et al Nat Neurosci. 2024 Jan 11. doi: 10.1038/

Oct. 21, 2024

Academic Institutions and Nonprofits only

#162375-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-jGCaMP8m-WPRE (#162375). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP8m-WPRE plasmid DNA. Syn-driven expression of calcium sensor GCaMP8m (faster, more sensitive). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

March 20, 2024

Academic Institutions and Nonprofits only

#164450-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP11851-pAAV-hDLX-minBG-iCre-4X2C-WPRE3-BGHpA (Alias: CN1851) (#164450). In addition to the viral particles, you will also receive purified AiP11851-pAAV-hDLX-minBG-iCre-4X2C-WPRE3-BGHpA (Alias: CN1851) plasmid DNA. minBetaGlobin-driven expression of Cre in forebrain GABAergic interneurons. For use in combination with Cre-dependent transgenic mouse lines or co-infection with Cre dependent viral vectors. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Graybuck et al Neuron. 2021 Mar 23. pii: S0896-6273(21)

Sept. 29, 2022

Academic Institutions and Nonprofits only

#137123-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6F (#137123). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6F plasmid DNA. EF1a-driven, Cre-dependent expression of GCaMP6f (inhibited in presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 5, 2021

Academic Institutions and Nonprofits only

#137126-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Fon-sRGECO (#137126). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Fon-sRGECO plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of cytosolic sRGECO calcium sensor. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#99130-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Sept. 18, 2019

Academic Institutions and Nonprofits only

#105557-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.CB7.CI.mCerulean.WPRE.RBG (#105557). In addition to the viral particles, you will also receive purified pENN.AAV.CB7.CI.mCerulean.WPRE.RBG plasmid DNA. CB7-driven mCerulean expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 25, 2018

Academic Institutions and Nonprofits only

#149415-AAV8

Ready-to-use AAV8 particles produced from pAAV-TBG-ER-TurboID (#149415). In addition to the viral particles, you will also receive purified pAAV-TBG-ER-TurboID plasmid DNA. TBG-driven expression of ER-localized TurboID (with HA and V5 tag). These AAV preparations are suitable purity for injection into animals.

Jonathan Long

Wei et al Nat Chem Biol. 2021 Mar;17(3):326-334. d

Aug. 6, 2025

Academic Institutions and Nonprofits only

#125712-AAV5

Ready-to-use AAV5 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

June 26, 2024

Academic Institutions and Nonprofits only

#185386-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_OT1.0 (#185386). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_OT1.0 plasmid DNA. hSyn-driven expression of the genetically-encoded fluorescent oxytocin(OT) sensor GRAB_OT1.0 in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Qian et al Nat Biotechnol. 2023 Jan 2. doi: 10.1038

June 26, 2024

Academic Institutions and Nonprofits only